Neutralizing monoclonal antibodies for treatment of COVID-19

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-...

Full description

Bibliographic Details
Main Authors: Taylor, PC, Adams, AC, Hufford, MM, De La Torre, I, Winthrop, K, Gottlieb, RL
Format: Journal article
Language:English
Published: Nature 2021